The Personalized Treatment Program Combines Molecular Profiling and Biomarker Testing while Monitoring Outcomes to Advance Science

WASHINGTON, D.C., UNITED STATES, April 6, 2021 /EINPresswire.com/ — The national nonprofit Colorectal Cancer Alliance (the Alliance) and Perthera, a precision oncology outcomes market leader, have partnered to provide molecular profiling with personalized treatment recommendations to improve patient outcomes. Together the organizations will enroll 500 patients in a clinical study to demonstrate the impact of precision oncology on colorectal cancer treatment, with a targeted focus on underserved populations who have lower access to high-quality care.

“The Alliance is committed to bringing innovation to our community as quickly as possible, with the number one goal of saving lives,” said Michael Sapienza, CEO of the Alliance. “Our Personalized Treatment Program, powered by Perthera’s Precision Oncology Platform, uses artificial intelligence to match patients with treatment options that will work best against their specific tumor. This is the same type of matching completed at world-class medical institutions, but our patients will receive it at no cost, no matter where they live.”

All patients who have had or will soon get biomarker testing can enroll, regardless of their location. If a patient has not been tested, Perthera’s clinical team will coordinate testing so the patient can enroll.

Once enrolled, patients and their care teams will receive life-saving resources, including Perthera’s precisely matched treatment recommendations proven to increase survival, clinical trial matching shown to increase enrollment at five times the national average, and the Alliance’s extensive patient support and navigation resources. This program further aims to capture and publish improved patient outcomes to advance medicine and science for patients now and in the future.

“We are thrilled to be launching this program with the Alliance, the leading patient advocacy organization dedicated to serving colorectal cancer patients and advancing high-quality cancer care, by driving our united campaign with and for patients across the country,” said Gary Gregory, CEO of Perthera. “We will build on the Alliance’s powerful efforts to significantly improve overall and progression-free survival rates and use real-world evidence to advance medical research. Working with the Alliance, we are enrolling physicians and patients across the U.S. in a distributed clinical study and improving patient outcomes, including those audiences with historically lower access to precision medicine.”

Colorectal cancer is the second leading cause of cancer-related deaths in the U.S. and the fourth most common cancer impacting both men and women. With the combined strength of these organizations, this collaborative program will dramatically impact this major form of cancer and create innovative solutions.

For More Information

To learn more about the program and how it is delivering the most comprehensive cancer care, please visit: https://www.ccalliance.org/patient-family-support/personalized-treatment-program